US5500420A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Metabotropic glutamate receptor agonists in the treatment of cerebral ischemia
Assignee: BARTO/JORDAN Inc
•
Filing: 1993-12-20
•
Granted: 1996-03-19
•
Expires: 2013-12-20
Abstract
Abstract Administration of metabotropic glutamate receptor agonists protect neuronal cells from death from cerebral ischemia. Examples of agents are L(+)-2-amino-4-phosphonobutyric acid, trans-amino cyclopentane dicarboxylic acid, (1S,3R)-amino cyclopentane dicarboxylic acid and quisqualic acid.
Inventors
- 👤 Kenneth Maiese
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 20:22
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/66; A61K31/662; A61K31/185; A61K31/19; A61K31/195; A61K31/196; A61K31/197; A61K31/198; A61K31/33; A61K31/395; A61K31/41; A61K31/4245; A61P; A61P25/00; A61P9/00; A61P9/10
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
37 words
A method of treatment of a subject currently afflicted with a stroke or previously afflicted with an ischemic event, said method comprising administering to said subject of a therapeutically effective amount of a metabotropic glutamate receptor agonist.
Claim 2
Independent Claim
37 words
A method of treatment of a subject currently afflicted with a stroke or previously afflicted with an ischemic event, said method comprising administering to said subject of a therapeutically effective amount of a metabotropic glutamate receptor agonist.
Claim 3
Independent Claim
62 words
A method of treatment of a subject currently afflicted with a stroke or previously afflicted with an ischemic event, said method comprising administering to said subject of a therapeutically effective amount of a metabotropic glutamate receptor agonist, said metabotropic glutamate receptor agonist being selected from the group consisting of L(+)-2-amino-4-phosphonobutyric acid, trans-amino cyclopentane dicarboxylic acid, (1S,3R)-amino cyclopentane dicarboxylic acid and quisqualic acid.
Claim 4
Independent Claim
62 words
A method of treatment of a subject currently afflicted with a stroke or previously afflicted with an ischemic event, said method comprising administering to said subject of a therapeutically effective amount of a metabotropic glutamate receptor agonist, said metabotropic glutamate receptor agonist being selected from the group consisting of L(+)-2-amino-4-phosphonobutyric acid, trans-amino cyclopentane dicarboxylic acid, (1S,3R)-amino cyclopentane dicarboxylic acid and quisqualic acid.
Claim 5
Dependent Claim
29 words
The method of claim 2 wherein the metabotropic glutamate receptor agonist is selected from the group consisting of L(+)-2-amino-4-phosphonobutyric acid, trans-amino cyclopentane dicarboxylic acid and (1S,3R)-amino cyclopentane dicarboxylic acid.
Claim 6
Dependent Claim
35 words
The method of claim 1 wherein the treatment is of a subject currently afflicted with a stroke, the administering is via a parenteral route and the therapeutically effective amount is a neuronal cell protecting amount.
Claim 7
Dependent Claim
20 words
The method of claim 4 wherein the administering is carried out within 6 hours of the onset of the stroke.
Claim 8
Dependent Claim
14 words
The method of claim 5 wherein the metabotropic glutamate receptor agonist is L(+)-2-amino-4-phosphonobutyric acid.
Claim 9
Dependent Claim
16 words
The method of claim 5 wherein the metabotropic glutamate receptor agonist is trans-amino cyclopentane dicarboxylic acid.
Claim 10
Dependent Claim
16 words
The method of claim 5 wherein the metabotropic glutamate receptor agonist is (1S,3R)-amino cyclopentane dicarboxylic acid.
Claim 11
Dependent Claim
14 words
The method of claim 5 wherein the metabotropic glutamate receptor agonist is quisqualic acid.
Claim 12
Dependent Claim
54 words
The method of claim 2 wherein the treatment is of a subject who previously was afflicted with an ischemic event and the therapeutically effective amount is one that provides an uninterrupted plasma level of a metabotropic glutamate receptor agonist in a neuronal cell protecting amount in the event of the occurrence of cerebral ischemia.
Claim 13
Dependent Claim
10 words
The method of claim 10 wherein the administering is orally.
Claim 14
Dependent Claim
14 words
The method of claim 11 wherein the metabotropic glutamate receptor agonist is L(+)-2-amino-4-phosphonobutyric acid.
Claim 15
Dependent Claim
16 words
The method of claim 11 wherein the metabotropic glutamate receptor agonist is trans-amino cyclopentane dicarboxylic acid.
Claim 16
Dependent Claim
16 words
The method of claim 11 wherein the metabotropic glutamate receptor agonist is (1S,3R)-amino cyclopentane dicarboxylic acid.
Claim 17
Dependent Claim
14 words
The method of claim 11 wherein the metabotropic glutamate receptor agonist is quisqualic acid.
References Cited (Backward Citations)
US5081123A
Cited
US5266594A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-03-19 | 1999-09-18 | 2000-03-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-03-19 | 2003-09-18 | 2004-03-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-03-19 | 2007-09-18 | 2008-03-19 | $7700.00 | Window Closed / Lapsed |